Use of spironolactone in the treatment of resistant arterial hypertension;Využití spironolaktonu v léčbě rezistentníarteriální hypertenze

Cor et Vasa

Volumn 53, Issue 6-7, 2011, Pages 343-347

  Václavík, Jan ^a   Kociánová, Eva ^a   Táborský, Miloš ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Hypertension; Mineralocorticoid receptor antagonists; Prediction of response to treatment; Resistant hypertension; Spironolactone

Indexed keywords

PLACEBO; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE FLUCTUATION; HUMAN; HYPERTENSION; PREDICTIVE VALUE; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 80053650195     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2011.085     Document Type: Review

References (31)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-1419.
2. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404. (Pubitemid 35469393)
3. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082. (Pubitemid 37430209)
4. Widimský J Jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. DoporučeníČeské společnosti pro hypertenzi. Vnitř Lék 2008;54:101-118.
5. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
6. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68.
7. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006.
8. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-825. (Pubitemid 17163442)
9. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev 2010 Aug 4;(8):CD008169.
10. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-3281.
11. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999;131:105-108. (Pubitemid 29340561)
12. Štrauch B, Petrák O, Zelinka T, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008;21:1086-1092.
13. Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-339. (Pubitemid 34408973)
14. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930. (Pubitemid 37315491)
15. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-487. (Pubitemid 41376826)
16. Sharabi Y, Adler E, Shamis A, et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006;19:750-755. (Pubitemid 43928519)
17. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-894. (Pubitemid 46398886)
18. Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845. (Pubitemid 351664214)
19. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30:418-424.
20. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, et al. Aldosterone excess or escape: Treating resistant hypertension. J Clin Hypertens (Greenwich) 2009;11:245-252.
21. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010;28:2329-2335.
22. De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147-152.
23. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010;4:290-294.
24. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011;22:75-78.
25. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007;25:747-750. (Pubitemid 46398868)
26. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) - study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155: v tisku. E-pub ahead of print, DOI 10.5507/bp.155.2011.004
27. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-1075.
28. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18:50-55. (Pubitemid 40187349)
29. London GM. Role of arterial wall properties in the pathogenesis of systolic hypertension. Am J Hypertens 2005;18:19S-22S. (Pubitemid 40416849)
30. Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens 2010;28:170-177.
31. Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich) 2011;13:120-130.